Centessa Corp (CNTA) - Cash per Single Share

Symbol and logo of brand Centessa Corp (CNTA)

Centessa Pharmaceuticals targets promising neurotreatment niches with colossal demand. The business model is based on outsourcing production through contract manufacturing plants, while development relies on a network of independent laboratories that overcome patent barriers. Cash per share for the issuer on the GURU.Markets dynamic chart illustrates liquidity, where the 1.79 mark reflects the latest data on capital reserves.

CNTA Centessa Corp: Cash Funds per Share in the range 07/04/2022 - 07/04/2026

Comprehensive metric breakdowns and analytics for Centessa Corp (CNTA)

Comprehensive company analysis:Centessa Pharmaceuticals
Finished products of Centessa Pharmaceuticals PLC

This metric is calculated by dividing total highly liquid assets by the total number of shares outstanding, determining the real value of a single instrument adjusted for cash basis. For Centessa Pharmaceuticals (CNTA), given its strong scientific reputation in rare disease therapy, the current cash per share serves as an indicator of financial stability, confirming the company's ability to fund costly research and development without excessive dilution.